Yuandong Biotech announced that a phase I/II clinical trial of the Class 1 innovative chemical drug HP-001 capsules and dexamethasone independently developed by the holding subsidiary Shanghai Chaoyang Pharmaceutical to treat patients with recurrent and difficult to treat multiple myeloma has recently completed the administration of the first test subject. HP-001 capsules are a novel oral CRBN-based molecular gum degrading agent. Its mechanism of action is to selectively recruit and degrade the transcription factor IKZF1/3, thereby activating the anti-tumor response. Preclinical studies have shown that HP-001 capsules are superior to approved IMIDs and next-generation drug candidates in terms of degradation efficacy and selectivity, have higher affinity for CRBN, and can overcome drug resistance mechanisms while minimizing both targeted and off-target toxicity.

Yuandong Biotech announced that a phase I/II clinical trial of the Class 1 innovative chemical drug HP-001 capsules and dexamethasone independently developed by the holding subsidiary Shanghai Chaoyang Pharmaceutical to treat patients with recurrent and difficult to treat multiple myeloma has recently completed the administration of the first test subject. HP-001 capsules are a novel oral CRBN-based molecular gum degrading agent. Its mechanism of action is to selectively recruit and degrade the transcription factor IKZF1/3, thereby activating the anti-tumor response. Preclinical studies have shown that HP-001 capsules are superior to approved IMIDs and next-generation drug candidates in terms of degradation efficacy and selectivity, have higher affinity for CRBN, and can overcome drug resistance mechanisms while minimizing both targeted and off-target toxicity.